As shown in Figure 1, 24 and 48 hrs of treatment with cetuximab (100 μg/ml) were found to affect cell viability only in CRC cells harbouring wild-type KRAS, BRAF and PIK3CA genes (CACO-2 and SW48), as expected. This evidence concerns the gene BRAF and colorectal carcinoma.